Developer docs
API playgroundTry for free, no card

Search company profiles

ProMed Pharma

Full company profile

uuid00664l5

Namestring
ProMed Pharma
Legal namestring
ProMed Pharma, LLC
Company typeenum
Private
Founded yearint
2006
Descriptiontext

ProMed Pharma is a privately held contract development and manufacturing organization (CDMO) headquartered in Maple Grove, Minnesota, established in 2006 as a sister entity to ProMed Molded Products (which has 30+ years of medical device molding history). The company is purpose-built around polymer-based long-acting injectable and implantable drug delivery dosage forms, serving both established pharmaceutical companies and early-stage biotechs, alongside medical device companies developing drug-device combination products. Its therapeutic reach spans ophthalmology, women's health, oncology, drug-device combination products, and macromolecule delivery, and it runs development programs with the Bill & Melinda Gates Foundation in the global health segment.

The technical platform is built on silicone, thermoplastic (EVA), and biodegradable (PLGA) polymer excipients, delivered through four core manufacturing capabilities: polymer-based controlled release, injection molding with API mixing, microextrusion (implants below 100 microns, coextrusion for near zero-order release), and proprietary Faros microsphere technology with tightly controlled 2–50 µm particle sizes and engineered release profiles from approximately 3 to over 180 days. Supporting capabilities include custom isolators for HPAPI handling (OEB Class 4+), DEA Schedule III registration (May 2025) for controlled substances, cGMP manufacturing compliant with 21 CFR 210/211 and 820, device assembly/packaging/sterilization, and an analytical and stability testing footprint exceeding 2,000 sq ft with HPLC, UPLC, GPC, FTIR, DSC, rheometry, viscometry, USP apparatus, and laser microscopy instrumentation.

ProMed operates a B2B enterprise field sales model with quote-based, project-specific pricing, dedicated project managers, and multi-year contract cadences. Revenue flows from development fees and manufacturing services spanning early-stage feasibility (10–20 projects per year, 4–8 week turnaround), tech transfer and scale-up, cGMP manufacturing, and analytical services. Physical footprint comprises Maple Grove HQ and a 20,000 sq ft development facility (established 2021), Plymouth manufacturing including ISO Class 7 suites (15,000+ sq ft), ProMed Development Center in Plymouth, the ProMed Caribe facility in Dorado, Puerto Rico, and most recently a 28,000 sq ft Niagara Lane plant acquired from Bora Pharmaceuticals in August 2025 that is being built out as a four-suite pharma condo model. Two of the four planned Niagara Lane suites were committed by undisclosed pharma partners in January and June 2026, and the SpineThera microsphere manufacturing assets were absorbed in April 2024.

Short descriptiontext

ProMed Pharma is a privately held CDMO specializing in polymer-based long-acting injectable and implantable drug delivery systems, serving pharmaceutical and medical device companies from feasibility through commercial cGMP manufacturing across multiple therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMaple Grove, United States
HQ citystring
Maple Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, long-acting injectables, polymer drug delivery, implantable dosage forms, drug-device combination products
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

ProMed Pharma generates revenue through contract development and manufacturing services for pharmaceutical and medical device companies. Services span the full product lifecycle from early-stage formulation feasibility (10-20 projects annually) through preclinical/toxicology supplies, clinical trial material, to commercial manufacturing. The company operates on a project-based model with dedicated manufacturing suite agreements and cGMP production contracts.

promedpharmallc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for development and manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on project scope including early-stage feasibility (4-8 week turnaround), tech transfer and scale-up, cGMP manufacturing, and analytical services. No public pricing tiers available.

promedpharmallc.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Faros™ Microsphere Technology
Description

Proprietary microsphere technology for sustained drug release formulations

promedpharmallc.com
Core offering1 text field

ProMed Pharma is a contract development and manufacturing organization (CDMO) that develops and manufactures polymer-based long-acting injectable and implantable dosage forms for pharmaceutical and medical device companies. The company offers end-to-end services from early-stage formulation feasibility (10–20 projects annually, 4–8 week turnaround) through tech transfer, scale-up, cGMP clinical and commercial manufacturing, device assembly/packaging/sterilization, and analytical and stability testing. Core technology platforms include silicone matrix, EVA polymer, and biodegradable PLGA microsphere drug delivery systems, with proprietary Faros™ microsphere technology and dedicated manufacturing suites for HPAPI handling.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Proof of concept demonstrated in 4-8 weeks for early-stage feasibility projects
+4 more records
Product overview1 text field

ProMed Pharma is a Contract Development and Manufacturing Organization (CDMO) specializing in long-acting injectable and implantable dosage forms. The company offers a comprehensive portfolio of polymer-based drug delivery services and technologies including Polymers for Controlled Release, Injection Molding, Extrusion, and Microspheres as core manufacturing capabilities. These capabilities are supported by integrated service offerings spanning Drug Product Feasibility, Tech Transfer/Scale-up, cGMP Manufacturing, Device Assembly/Packaging/Sterilization, and Analytical & Stability Testing. The company applies these technologies across key application areas including Ophthalmology, Women's Health, Oncology, Drug-Device Combination Products, and Macromolecule Delivery. Notable named technologies include the Faros™ Microsphere Technology for sustained-release formulations.

Product and service7 records
1Drug Product Feasibility
CategoryCDMO Development Service
Description

Early-stage formulation and proof-of-concept service demonstrating drug delivery approaches in 4–8 weeks for pharmaceutical and medical device companies; handles approximately 10–20 feasibility projects annually.

2Tech Transfer, Optimization & Scale-up
CategoryCDMO Development Service
Description

Service transitioning programs from feasibility to production-level manufacturing, including process optimization, product sterilization definition, analytical method pre-validation, and preliminary stability testing.

3cGMP Manufacturing
CategoryCDMO Manufacturing Service
Description

Full cGMP manufacturing services compliant with 21 CFR 211, including material handling, cleanroom monitoring, equipment operation, process parameters, and product release for clinical and commercial supply.

4Device Assembly, Packaging, and Sterilization
CategoryCDMO Manufacturing Service
Description

Service assembling dosage forms into applicators, performing primary packaging, and managing sterilization logistics including gamma, e-beam, and ethylene oxide methods.

5Analytical & Stability Testing
CategoryCDMO Analytical Service
Description

Comprehensive analytical testing including drug assay, impurities, content uniformity, in vitro elution testing, mechanical testing, and dimensional characterization, supported by a 2,000+ sq ft analytical laboratory equipped with HPLC, UPLC, GPC, FTIR, DSC, Karl Fischer, rheometry, viscometry, USP apparatus, laser microscopy, and tensile testing.

6Faros™ Microsphere Technology
CategoryProprietary Drug Delivery Platform
Description

Proprietary microsphere technology platform for sustained-release drug delivery, producing tightly controlled 2–50 µm spherical non-aggregating particles with engineered release profiles from approximately 3 to over 180 days; compatible with small molecule APIs and peptides, deliverable at concentrations above 800 mg/ml through needles as small as 30G.

7Resorbable Long-Acting Contraceptive Implant (Development Program)
CategoryWomen's Health Drug Delivery
Description

Development program for a novel fully resorbable contraceptive implant providing 18 months of contraception and eliminating the need for clinic removal, funded by the Bill & Melinda Gates Foundation and targeted at low and middle income countries.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Undisclosed Pharmaceutical Partner (HPAPI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

An undisclosed pharmaceutical partner committed to a second dedicated manufacturing suite at Niagara Lane facility. The suite is specifically configured for highly potent active pharmaceutical ingredients (HPAPIs) and will support development and future commercial production of complex generic drug products. Incorporates advanced containment technologies and environmental controls for potent compound processing.

promedpharmallc.com
2Undisclosed Late-Stage Pharmaceutical Partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

An undisclosed pharmaceutical partner committed to a dedicated manufacturing suite at the new Niagara Lane facility. The partner is entering late-stage clinical trials with intent for commercial production pending approval. This represents the first of four planned manufacturing suites at Niagara Lane for ophthalmic implants and sustained-release drug delivery products.

promedpharmallc.com
Strategic tierCoreTypeOthersAnnounced on2025-08-01
Description

ProMed Pharma acquired a 28,000 square foot pharmaceutical manufacturing facility from Bora Pharmaceuticals located at 2200 N Niagara Lane, Plymouth, Minnesota. The facility includes advanced infrastructure for GMP-compliant production with controlled warehousing, Grade C and D manufacturing space, and expansion capacity. The acquisition significantly expanded ProMed Pharma's commercial manufacturing footprint.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

ProMed Pharma acquired SpineThera's cGMP manufacturing operational assets including a controlled environment manufacturing suite, process equipment, and obtained an option to license microsphere intellectual property. SpineThera retains ownership of SX600 IP and becomes a customer of ProMed for manufacturing its lead asset, dexamethasone microspheres for epidural injection. SpineThera's experienced manufacturing team joined ProMed Pharma.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Evonik Health Care
TypeDirect peer
Description

Evonik Health Care offers polymer-based drug delivery CDMO services including PLGA, bioresorbable polymers, and contract manufacturing for complex parenteral and long-acting injectable dosage forms. Direct competitor to ProMed in polymer CDMO with overlapping capabilities in microspheres and sustained-release formulations.

TypeEmerging player
Description

SpineThera is a clinical-stage pharmaceutical developer of sustained-release injectable therapies (SX600 dexamethasone microspheres) whose manufacturing assets were acquired by ProMed in 2024. Now operates as a customer of ProMed and an option licensor of microsphere IP, creating a tightly coupled emerging player relationship.

TypeDirect peer
Description

Ascendia Pharma Solutions is a specialty CDMO offering pre-formulation, formulation development, and cGMP manufacturing of injectables including nanoemulsions, nanosuspensions, and lyophilized products. Comparable mid-sized CDMO serving similar early- to commercial-stage injectable customers.

TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs offering softgel, oral, injectable, and biologic drug delivery services, including long-acting injectable and implant capabilities. It competes with ProMed for pharmaceutical contract manufacturing customers but across a much broader portfolio and at greater scale.

TypeBroad incumbent
Description

Lonza is a leading global CDMO with capabilities across small molecules, biologics, and drug product services including complex parenteral formulations. Competes with ProMed for commercial-scale sterile injectable and specialty drug product contracts at much larger scale.

TypeBroad incumbent
Description

Patheon, part of Thermo Fisher's pharma services, is a large global CDMO offering drug substance, drug product, and packaging services including sterile injectables. It overlaps with ProMed on injectable and combination product manufacturing but serves a much broader market and customer base.

TypeDirect peer
Description

Exela Pharma Sciences is a specialty CDMO focused on sterile injectable and lyophilized drug products for pharmaceutical clients. Direct competitor to ProMed in complex parenteral CDMO services with comparable mid-market positioning.

TypeDirect peer
Description

Oakwood Labs is a privately held specialty CDMO focused on polymer-based long-acting injectable formulations, including microspheres and biodegradable implants. Closest peer in scale and technology focus to ProMed, serving similar pharmaceutical customers with sustained-release parenteral dosage forms.

TypeDirect peer
Description

Halo Pharma is a US-based CDMO providing oral solid, liquid, and topical dosage form development and manufacturing. Comparable mid-market CDMO serving pharmaceutical customers across development and commercial stages with overlap in specialty dosage forms.

10Tapemark
TypeDirect peer
Description

Tapemark is a privately held CDMO specializing in transdermal patches, topical, and oral dissolvable films with cGMP manufacturing capabilities. Comparable mid-sized specialty CDMO focused on complex non-oral drug delivery dosage forms serving pharmaceutical customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProMed Pharma

Pharmaceutical Contract Development and Manufacturing (CDMO)promedpharmallc.com

ProMed Pharma is a privately held CDMO specializing in polymer-based long-acting injectable and implantable drug delivery systems, serving pharmaceutical and medical device companies from feasibility through commercial cGMP manufacturing across multiple therapeutic areas.

What ProMed Pharma does

ProMed Pharma is a privately held contract development and manufacturing organization (CDMO) headquartered in Maple Grove, Minnesota, established in 2006 as a sister entity to ProMed Molded Products (which has 30+ years of medical device molding history). The company is purpose-built around polymer-based long-acting injectable and implantable drug delivery dosage forms, serving both established pharmaceutical companies and early-stage biotechs, alongside medical device companies developing drug-device combination products. Its therapeutic reach spans ophthalmology, women's health, oncology, drug-device combination products, and macromolecule delivery, and it runs development programs with the Bill & Melinda Gates Foundation in the global health segment.

The technical platform is built on silicone, thermoplastic (EVA), and biodegradable (PLGA) polymer excipients, delivered through four core manufacturing capabilities: polymer-based controlled release, injection molding with API mixing, microextrusion (implants below 100 microns, coextrusion for near zero-order release), and proprietary Faros microsphere technology with tightly controlled 2–50 µm particle sizes and engineered release profiles from approximately 3 to over 180 days. Supporting capabilities include custom isolators for HPAPI handling (OEB Class 4+), DEA Schedule III registration (May 2025) for controlled substances, cGMP manufacturing compliant with 21 CFR 210/211 and 820, device assembly/packaging/sterilization, and an analytical and stability testing footprint exceeding 2,000 sq ft with HPLC, UPLC, GPC, FTIR, DSC, rheometry, viscometry, USP apparatus, and laser microscopy instrumentation.

ProMed operates a B2B enterprise field sales model with quote-based, project-specific pricing, dedicated project managers, and multi-year contract cadences. Revenue flows from development fees and manufacturing services spanning early-stage feasibility (10–20 projects per year, 4–8 week turnaround), tech transfer and scale-up, cGMP manufacturing, and analytical services. Physical footprint comprises Maple Grove HQ and a 20,000 sq ft development facility (established 2021), Plymouth manufacturing including ISO Class 7 suites (15,000+ sq ft), ProMed Development Center in Plymouth, the ProMed Caribe facility in Dorado, Puerto Rico, and most recently a 28,000 sq ft Niagara Lane plant acquired from Bora Pharmaceuticals in August 2025 that is being built out as a four-suite pharma condo model. Two of the four planned Niagara Lane suites were committed by undisclosed pharma partners in January and June 2026, and the SpineThera microsphere manufacturing assets were absorbed in April 2024.

ProMed Pharma firmographics

Firmographics
Name
ProMed Pharma
Legal name
ProMed Pharma, LLC
Website
https://promedpharmallc.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
ProMed Pharma is a privately held CDMO specializing in polymer-based long-acting injectable and implantable drug delivery systems, serving pharmaceutical and medical device companies from feasibility through commercial cGMP manufacturing across multiple therapeutic areas.
Ownership category
akta.pro rank

ProMed Pharma industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Long-acting injectables
  • Polymer drug delivery
  • Implantable dosage forms
  • Drug-device combination products

Where ProMed Pharma is headquartered

Location

Headquarters

HQ city
Maple Grove
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ProMed Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: ProMed Pharma generates revenue through contract development and manufacturing services for pharmaceutical and medical device companies. Services span the full product lifecycle from early-stage formulation feasibility (10-20 projects annually) through preclinical/toxicology supplies, clinical trial material, to commercial manufacturing. The company operates on a project-based model with dedicated manufacturing suite agreements and cGMP production contracts.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for development and manufacturing services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ProMed Pharma product offering

Product offering

Core offering

ProMed Pharma is a contract development and manufacturing organization (CDMO) that develops and manufactures polymer-based long-acting injectable and implantable dosage forms for pharmaceutical and medical device companies. The company offers end-to-end services from early-stage formulation feasibility (10–20 projects annually, 4–8 week turnaround) through tech transfer, scale-up, cGMP clinical and commercial manufacturing, device assembly/packaging/sterilization, and analytical and stability testing. Core technology platforms include silicone matrix, EVA polymer, and biodegradable PLGA microsphere drug delivery systems, with proprietary Faros™ microsphere technology and dedicated manufacturing suites for HPAPI handling.

Product overview

ProMed Pharma is a Contract Development and Manufacturing Organization (CDMO) specializing in long-acting injectable and implantable dosage forms. The company offers a comprehensive portfolio of polymer-based drug delivery services and technologies including Polymers for Controlled Release, Injection Molding, Extrusion, and Microspheres as core manufacturing capabilities. These capabilities are supported by integrated service offerings spanning Drug Product Feasibility, Tech Transfer/Scale-up, cGMP Manufacturing, Device Assembly/Packaging/Sterilization, and Analytical & Stability Testing. The company applies these technologies across key application areas including Ophthalmology, Women's Health, Oncology, Drug-Device Combination Products, and Macromolecule Delivery. Notable named technologies include the Faros™ Microsphere Technology for sustained-release formulations.

Differentiator

Problem solved

Functional benefit

Brands

  • Faros™ Microsphere Technology: Proprietary microsphere technology for sustained drug release formulations

Products and services

  • Drug Product Feasibility Early-stage formulation and proof-of-concept service demonstrating drug delivery approaches in 4–8 weeks for pharmaceutical and medical device companies; handles approximately 10–20 feasibility projects annually.
  • Tech Transfer, Optimization & Scale-up Service transitioning programs from feasibility to production-level manufacturing, including process optimization, product sterilization definition, analytical method pre-validation, and preliminary stability testing.
  • cGMP Manufacturing Full cGMP manufacturing services compliant with 21 CFR 211, including material handling, cleanroom monitoring, equipment operation, process parameters, and product release for clinical and commercial supply.
  • Device Assembly, Packaging, and Sterilization Service assembling dosage forms into applicators, performing primary packaging, and managing sterilization logistics including gamma, e-beam, and ethylene oxide methods.
  • Analytical & Stability Testing Comprehensive analytical testing including drug assay, impurities, content uniformity, in vitro elution testing, mechanical testing, and dimensional characterization, supported by a 2,000+ sq ft analytical laboratory equipped with HPLC, UPLC, GPC, FTIR, DSC, Karl Fischer, rheometry, viscometry, USP apparatus, laser microscopy, and tensile testing.
  • Faros™ Microsphere Technology Proprietary microsphere technology platform for sustained-release drug delivery, producing tightly controlled 2–50 µm spherical non-aggregating particles with engineered release profiles from approximately 3 to over 180 days; compatible with small molecule APIs and peptides, deliverable at concentrations above 800 mg/ml through needles as small as 30G.
  • Resorbable Long-Acting Contraceptive Implant (Development Program) Development program for a novel fully resorbable contraceptive implant providing 18 months of contraception and eliminating the need for clinic removal, funded by the Bill & Melinda Gates Foundation and targeted at low and middle income countries.

Quantifiable outcome

  • Proof of concept demonstrated in 4-8 weeks for early-stage feasibility projects
  • +4 more outcomes

Companies that use ProMed Pharma

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

ProMed Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

ProMed Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Undisclosed Pharmaceutical Partner (HPAPI)coreStrategic or Co-development Partner · 1 June 2026An undisclosed pharmaceutical partner committed to a second dedicated manufacturing suite at Niagara Lane facility. The suite is specifically configured for highly potent active pharmaceutical ingredients (HPAPIs) and will support development and future commercial production of complex generic drug products. Incorporates advanced containment technologies and environmental controls for potent compound processing.
  • Undisclosed Late-Stage Pharmaceutical PartnercoreStrategic or Co-development Partner · 1 January 2026An undisclosed pharmaceutical partner committed to a dedicated manufacturing suite at the new Niagara Lane facility. The partner is entering late-stage clinical trials with intent for commercial production pending approval. This represents the first of four planned manufacturing suites at Niagara Lane for ophthalmic implants and sustained-release drug delivery products.
  • Bora PharmaceuticalscoreOthers · 1 August 2025ProMed Pharma acquired a 28,000 square foot pharmaceutical manufacturing facility from Bora Pharmaceuticals located at 2200 N Niagara Lane, Plymouth, Minnesota. The facility includes advanced infrastructure for GMP-compliant production with controlled warehousing, Grade C and D manufacturing space, and expansion capacity. The acquisition significantly expanded ProMed Pharma's commercial manufacturing footprint.
  • SpineThera Inc.coreStrategic or Co-development Partner · 1 April 2024ProMed Pharma acquired SpineThera's cGMP manufacturing operational assets including a controlled environment manufacturing suite, process equipment, and obtained an option to license microsphere intellectual property. SpineThera retains ownership of SX600 IP and becomes a customer of ProMed for manufacturing its lead asset, dexamethasone microspheres for epidural injection. SpineThera's experienced manufacturing team joined ProMed Pharma.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

ProMed Pharma competitors and assessment

Company assessment

Direct peers

  • Evonik Health Care: Evonik Health Care offers polymer-based drug delivery CDMO services including PLGA, bioresorbable polymers, and contract manufacturing for complex parenteral and long-acting injectable dosage forms. Direct competitor to ProMed in polymer CDMO with overlapping capabilities in microspheres and sustained-release formulations.
  • Ascendia Pharma Solutions: Ascendia Pharma Solutions is a specialty CDMO offering pre-formulation, formulation development, and cGMP manufacturing of injectables including nanoemulsions, nanosuspensions, and lyophilized products. Comparable mid-sized CDMO serving similar early- to commercial-stage injectable customers.
  • Exela Pharma Sciences: Exela Pharma Sciences is a specialty CDMO focused on sterile injectable and lyophilized drug products for pharmaceutical clients. Direct competitor to ProMed in complex parenteral CDMO services with comparable mid-market positioning.
  • Oakwood Labs: Oakwood Labs is a privately held specialty CDMO focused on polymer-based long-acting injectable formulations, including microspheres and biodegradable implants. Closest peer in scale and technology focus to ProMed, serving similar pharmaceutical customers with sustained-release parenteral dosage forms.
  • Halo Pharma (Noble Pharma): Halo Pharma is a US-based CDMO providing oral solid, liquid, and topical dosage form development and manufacturing. Comparable mid-market CDMO serving pharmaceutical customers across development and commercial stages with overlap in specialty dosage forms.
  • Tapemark: Tapemark is a privately held CDMO specializing in transdermal patches, topical, and oral dissolvable films with cGMP manufacturing capabilities. Comparable mid-sized specialty CDMO focused on complex non-oral drug delivery dosage forms serving pharmaceutical customers.

Emerging players

  • SpineThera Inc. SpineThera is a clinical-stage pharmaceutical developer of sustained-release injectable therapies (SX600 dexamethasone microspheres) whose manufacturing assets were acquired by ProMed in 2024. Now operates as a customer of ProMed and an option licensor of microsphere IP, creating a tightly coupled emerging player relationship.

Broad incumbents

  • Catalent (Novo Holdings): Catalent is one of the largest global CDMOs offering softgel, oral, injectable, and biologic drug delivery services, including long-acting injectable and implant capabilities. It competes with ProMed for pharmaceutical contract manufacturing customers but across a much broader portfolio and at greater scale.
  • Lonza (Small Molecules CDMO): Lonza is a leading global CDMO with capabilities across small molecules, biologics, and drug product services including complex parenteral formulations. Competes with ProMed for commercial-scale sterile injectable and specialty drug product contracts at much larger scale.
  • Patheon (Thermo Fisher Scientific): Patheon, part of Thermo Fisher's pharma services, is a large global CDMO offering drug substance, drug product, and packaging services including sterile injectables. It overlaps with ProMed on injectable and combination product manufacturing but serves a much broader market and customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ProMed Pharma compliance and trust

Trust signal

Compliance5 records

ProMed Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProMed Pharma leadership team

Management profile

Number of profiles

Profiles2 records

ProMed Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ProMed Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProMed Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProMed Pharma

What does ProMed Pharma do?

ProMed Pharma is a contract development and manufacturing organization (CDMO) that develops and manufactures polymer-based long-acting injectable and implantable dosage forms for pharmaceutical and medical device companies. The company offers end-to-end services from early-stage formulation feasibility (10–20 projects annually, 4–8 week turnaround) through tech transfer, scale-up, cGMP clinical and commercial manufacturing, device assembly/packaging/sterilization, and analytical and stability testing. Core technology platforms include silicone matrix, EVA polymer, and biodegradable PLGA microsphere drug delivery systems, with proprietary Faros™ microsphere technology and dedicated manufacturing suites for HPAPI handling.

Is ProMed Pharma a public or private company?

ProMed Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ProMed Pharma founded?

ProMed Pharma was founded in 2006. It employs 1 to 10 people.

Where is ProMed Pharma based?

ProMed Pharma is headquartered in Maple Grove, United States, in the North America region.

How does ProMed Pharma make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are ProMed Pharma's main competitors?

Direct peers on record are Evonik Health Care, Ascendia Pharma Solutions, Exela Pharma Sciences, Oakwood Labs, Halo Pharma (Noble Pharma) and Tapemark. SpineThera Inc. is listed as an emerging player. Broad incumbents are Catalent (Novo Holdings), Lonza (Small Molecules CDMO) and Patheon (Thermo Fisher Scientific).

Does ProMed Pharma have an API?

No public API is recorded for ProMed Pharma.

What industry is ProMed Pharma in?

ProMed Pharma's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals